"June 16th, @ 5:51 am PDTGoldman Sachs initiates coverage on Natera (NTRA)...+2.87...We are not invisible...We appear on the same report."
Goldman Sachs Initiates Coverage on Natera, Inc. (NTRA)
"On June 4, Natera, Inc. (NASDAQ:NTRA) announced a collaboration with CytoDyn to evaluate circulating tumor DNA dynamics in metastatic colorectal cancer. Under the agreement, Natera said it will examine CLOVER Phase 2 trial samples using its Signatera assay. It will also deliver real-world data insights drawn from a database exceeding 2 million plasma timepoints.
CytoDyn CEO Jacob Lalezari said the partnership will generate insights into "ctDNA response kinetics and disease progression." Natera's Vice President, Biopharma Data & AI Partnering, Matt Love, added that the platform helps partners "better understand disease biology, treatment response, and patient outcomes."
https://finance.yahoo.com/markets/stocks/arti...36267.html